[ad_1] Shares of Dr. Reddy’s Laboratories Ltd. declined over 5% during Friday’s early trading session after the company announced its December quarter results. The Q3 earnings revealed subdued numbers and margins, reflecting the impact of heightened competition in the generics segment. Company Value Change %Change The drugmaker reported EBITDA margin of 27.5% for the quarter, […]
Stock Market Crash: The two Nifty stocks that still delivered positive returns this week – CNBC TV18
[ad_1] The Indian equity market recorded its biggest weekly fall in more than two years. The Nifty and Sensex fell over 4% each, marking their steepest decline since June 2022. The Nifty Bank index slid 5%, while the Midcap index declined nearly 4% this week. Company Value Change %Change All BSE-listed companies erased a market […]
UBS advises ‘selling’ a bunch of Pharma stocks – CNBC TV18
[ad_1] Shares of pharma companies will be in focus during Friday’s trading session as global brokerage firm UBS has initiated coverage on the pharma sector. UBS mentioned that trends are weakening in both India and the US. UBS has initiated coverage on Zydus Lifesciences Ltd. and Dr Reddy’s Laboratories Ltd. with a ‘Sell’ recommendation, setting […]
FDA ends Dr Reddy’s Hyderabad R&D unit scan with zero observation – CNBC TV18
[ad_1] Drug makers Dr Reddy’s Laboratories Ltd (DRL) on Friday (September 20) said the United States Food & Drug Administration (FDA) has completed a routine Good Manufacturing Practice (GMP) inspection at its integrated product development organisation (IPDO) in Bachupally, Hyderabad. “This is to inform you that the United States Food & Drug Administration (USFDA) today […]
Dr Reddy’s Labs gets VAI classification for Andhra Pradesh facility from USFDA – CNBC TV18
[ad_1] Dr Reddy’s Laboratories Ltd on Friday, September 6, announced that it has received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh. The inspection has been classified as “Voluntary Action Indicated” (VAI) by the US drug regulator, meaning that while some […]